FDA approves new treatment for refractory multiple myeloma

FDA grants accelerated approval to Xpovio (selinexor) tablets in combination with the corticosteroid dexamethasone for the treatment of adult patients with relapsed refractory multiple myeloma (RRMM) who have received at least four prior therapies and whose disease is resistant to several other form

Source: FDA Center for Drug Evaluation and Research - What's New - July 3, 2019 Category: Drugs & Pharmacology Authors: FDA Source Type: news